Altay Therapeutics
YC W20San Francisco, US · Founded 2019 · 6 employees · 3 known investors
Altay Therapeutics develops small molecule inhibitors targeting transcription factors to treat serious diseases including facioscapulohumeral muscular dystrophy and cancer. The company's pipeline includes oral drug candidates designed as first- or best-in-class therapeutics for oncology and inflammatory conditions.
BiotechDigital HealthHealthtechMedical DevicesAI-powered Drug DiscoveryTherapeuticsDrug discoveryin /69914567/admin/feed/posts/@ycombinatorycombinator.com ↗
Founders & leadership· Y Combinator alumni (W20)
Investors · 3
Competitors · 7
by search overlapPatSnap74 shared keywordsPatsnap builds an AI-powered platform for R&D, IP, and innovation intelligence, offering tools for patent search, novelty and FTO analysis, patent drafting, and materials and pharma research. It serves R&D leaders, IP professionals, engineers, and scientists across industries including materials, manufacturing, life sciences, pharmaceuticals, and consumer goods.
Eli Lilly47 shared keywords
Cowles_Investments_StemCentrx40 shared keywordsFierce Biotech is a news publication covering the biotechnology, pharmaceutical, and medtech industries, reporting on clinical trials, deals, venture capital, drug development, and research. It serves industry professionals through articles, special reports, events, webinars, and podcasts.
Diabetes Prevention Program38 shared keywords
Bioworld34 shared keywordsBioWorld publishes news and data on the biopharmaceutical and drug development industry, covering topics such as clinical trials, licensing deals, oncology pipelines, and gene therapies. It serves biopharma and life sciences professionals through industry reporting and market intelligence.
Coya Therapeutics30 shared keywords
Alloy22 shared keywordsAlloy provides drug discovery services and platform technologies across genetic medicines, TCR mimics, and cell therapies, supporting pharmaceutical partners in developing novel treatments.
Companies competing with Altay Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Science Foundation | Phase I | 2023 | $275K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $399.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $299.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $299.1K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
- SOLVE FSHD invests US$3 million in Altay Therapeuticsfinance.yahoo.com · 2022